BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weintraub WS, Lüscher TF, Pocock S. The perils of surrogate endpoints. Eur Heart J 2015;36:2212-8. [PMID: 25975658 DOI: 10.1093/eurheartj/ehv164] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Rossello X, Yellon DM. A critical review on the translational journey of cardioprotective therapies! International Journal of Cardiology 2016;220:176-84. [DOI: 10.1016/j.ijcard.2016.06.131] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
2 Welsh P, Grassia G, Botha S, Sattar N, Maffia P. Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? Br J Pharmacol 2017;174:3898-913. [PMID: 28409825 DOI: 10.1111/bph.13818] [Cited by in Crossref: 90] [Cited by in F6Publishing: 79] [Article Influence: 18.0] [Reference Citation Analysis]
3 Campbell MJ, Lancaster GA, Eldridge SM. A randomised controlled trial is not a pilot trial simply because it uses a surrogate endpoint. Pilot Feasibility Stud 2018;4:130. [PMID: 30069309 DOI: 10.1186/s40814-018-0324-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Anderer A, Bastani H, Silberholz J. Adaptive Clinical Trial Designs with Surrogates: When Should We Bother? Management Science. [DOI: 10.1287/mnsc.2021.4096] [Reference Citation Analysis]
5 Pocock SJ, Clayton TC, Stone GW. Design of Major Randomized Trials: Part 3 of a 4-Part Series on Statistics for Clinical Trials. J Am Coll Cardiol 2015;66:2757-66. [PMID: 26700838 DOI: 10.1016/j.jacc.2015.10.036] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
6 Lüscher TF. Predictors as well as surrogate and hard endpoints in cardiovascular disease. Eur Heart J 2015;36:2197-9. [DOI: 10.1093/eurheartj/ehv327] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
7 Khera R, Girotra S. Cerebral Embolic Protection Devices in Transcatheter Aortic Valve Replacement-Effective in Stroke Prevention? JAMA Intern Med 2020;180:785-6. [PMID: 32091530 DOI: 10.1001/jamainternmed.2019.6763] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
8 O'Fee K, Deych E, Ciani O, Brown DL. Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials. JAMA Intern Med 2021. [PMID: 34694318 DOI: 10.1001/jamainternmed.2021.5726] [Reference Citation Analysis]
9 Timmis A, Raharja A, Archbold RA, Mathur A. Validity of inducible ischaemia as a surrogate for adverse outcomes in stable coronary artery disease. Heart 2018;104:1733-8. [PMID: 29875140 DOI: 10.1136/heartjnl-2018-313230] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
10 Wang NC, Li JZ, Adelstein EC, Althouse AD, Sharbaugh MS, Jain SK, Mendenhall GS, Shalaby AA, Voigt AH, Saba S. New-onset left bundle branch block-associated idiopathic nonischemic cardiomyopathy and time from diagnosis to cardiac resynchronization therapy: The NEOLITH II study. Pacing Clin Electrophysiol 2018;41:143-54. [DOI: 10.1111/pace.13264] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
11 Hyun MK, Kan M. The Association Between Work Status and the Use of Healthcare Services Among Women in the Republic of Korea. Safety and Health at Work 2021. [DOI: 10.1016/j.shaw.2021.10.004] [Reference Citation Analysis]
12 Szczesniak R, Turkovic L, Andrinopoulou ER, Tiddens HAWM. Chest imaging in cystic fibrosis studies: What counts, and can be counted? J Cyst Fibros 2017;16:175-85. [PMID: 28040479 DOI: 10.1016/j.jcf.2016.12.008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
13 Meneveau N, Souteyrand G, Motreff P, Caussin C, Amabile N, Ohlmann P, Morel O, Lefrançois Y, Descotes-Genon V, Silvain J, Braik N, Chopard R, Chatot M, Ecarnot F, Tauzin H, Van Belle E, Belle L, Schiele F. Optical Coherence Tomography to Optimize Results of Percutaneous Coronary Intervention in Patients with Non-ST-Elevation Acute Coronary Syndrome: Results of the Multicenter, Randomized DOCTORS Study (Does Optical Coherence Tomography Optimize Results of Stenting). Circulation 2016;134:906-17. [PMID: 27573032 DOI: 10.1161/CIRCULATIONAHA.116.024393] [Cited by in Crossref: 122] [Cited by in F6Publishing: 29] [Article Influence: 20.3] [Reference Citation Analysis]
14 Fischbacher CM, Lewsey J, Muirie J, McCartney G. A critical reflection on the use of improvement science approaches in public health. Scand J Public Health 2021;:1403494821990245. [PMID: 33596733 DOI: 10.1177/1403494821990245] [Reference Citation Analysis]
15 Foster DR, Sowinski KM. Part II : Statistics in practice: Study design and application of inferential statistics—Interventional research. J Am Coll Clin Pharm 2022;5:377-81. [DOI: 10.1002/jac5.1613] [Reference Citation Analysis]
16 Lysaght T. Accelerating regenerative medicine: the Japanese experiment in ethics and regulation. Regenerative Medicine 2017;12:657-68. [DOI: 10.2217/rme-2017-0038] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
17 Drexel H, Rosano GMC, Lewis BS, Huber K, Vonbank A, Dopheide JF, Mader A, Niessner A, Savarese G, Wassmann S, Agewall S. The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials. European Heart Journal - Cardiovascular Pharmacotherapy 2020;6:97-103. [DOI: 10.1093/ehjcvp/pvz029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
18 Luz A, Silveira I, Brochado B, Rodrigues P, João Sousa M, Santos R, Trêpa M, Santos M, Silveira J, Torres S, Leite-Moreira AF, Carvalho H. Manual thrombectomy efficiency in relationship to the area at risk in patients with myocardial infarction with TIMI 0-1 coronary flow: Insights from an all comers registry. Catheter Cardiovasc Interv 2017;90:531-9. [PMID: 28191743 DOI: 10.1002/ccd.26959] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
19 Kurdi AI, Elliott RA, Chen L. Clinical and economic implications of therapeutic switching of angiotensin receptor blockers to angiotensin-converting enzyme inhibitors: a population-based study. Journal of Hypertension 2019;37:1285-93. [DOI: 10.1097/hjh.0000000000002009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
20 Weintraub WS. Perspective on Trends in Statin Use. JAMA Cardiol 2017;2:11-2. [PMID: 27842177 DOI: 10.1001/jamacardio.2016.4710] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
21 Warner JJ, Crook HL, Whelan KM, Bleser WK, Roiland RA, Hamilton Lopez M, Saunders RS, Wang TY, Hernandez AF, Mcclellan MB, Califf RM, Brown N; the American Heart Association Partnering with Regulators Learning Collaborative*. Improving Cardiovascular Drug and Device Development and Evidence Through Patient-Centered Research and Clinical Trials: A Call to Action From the Value in Healthcare Initiative’s Partnering With Regulators Learning Collaborative. Circ: Cardiovascular Quality and Outcomes 2020;13. [DOI: 10.1161/circoutcomes.120.006606] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
22 Patel RB, Vaduganathan M, Samman-Tahhan A, Kalogeropoulos AP, Georgiopoulou VV, Fonarow GC, Gheorghiade M, Butler J. Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. Am J Cardiol 2016;117:1845-50. [PMID: 27085935 DOI: 10.1016/j.amjcard.2016.03.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
23 Candlish J, Pate A, Sperrin M, van Staa T; GetReal Work Package 2. Evaluation of biases present in the cohort multiple randomised controlled trial design: a simulation study. BMC Med Res Methodol 2017;17:17. [PMID: 28143408 DOI: 10.1186/s12874-017-0295-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
24 Byrne P, O’donovan Ó, Smith SM, Cullinan J. Medicalisation, risk and the use of statins for primary prevention of cardiovascular disease: a scoping review of the literature. Health, Risk & Society 2019;21:390-406. [DOI: 10.1080/13698575.2019.1667964] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
25 Davillas A, Jones AM. Ex ante inequality of opportunity in health, decomposition and distributional analysis of biomarkers. J Health Econ 2020;69:102251. [PMID: 31896483 DOI: 10.1016/j.jhealeco.2019.102251] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
26 Chia PY, Teo A, Yeo TW. Overview of the Assessment of Endothelial Function in Humans. Front Med (Lausanne) 2020;7:542567. [PMID: 33117828 DOI: 10.3389/fmed.2020.542567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 McClellan M, Brown N, Califf RM, Warner JJ. Call to Action: Urgent Challenges in Cardiovascular Disease: A Presidential Advisory From the American Heart Association. Circulation 2019;139:e44-54. [PMID: 30674212 DOI: 10.1161/CIR.0000000000000652] [Cited by in Crossref: 60] [Cited by in F6Publishing: 27] [Article Influence: 20.0] [Reference Citation Analysis]
28 Ahmad T, Riello RJ, Inzucchi SE. A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease. Eur Cardiol 2021;16:e11. [PMID: 33897837 DOI: 10.15420/ecr.2020.01.R1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Correia LC. Ezetimibe: Clinical and Scientific Meaning of the IMPROVE-IT Study. Arq Bras Cardiol 2016;106:247-9. [PMID: 27027368 DOI: 10.5935/abc.20160033] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Ottaviani JI, Fong R, Kimball J, Ensunsa JL, Britten A, Lucarelli D, Luben R, Grace PB, Mawson DH, Tym A, Wierzbicki A, Khaw KT, Schroeter H, Kuhnle GGC. Evaluation at scale of microbiome-derived metabolites as biomarker of flavan-3-ol intake in epidemiological studies. Sci Rep 2018;8:9859. [PMID: 29959422 DOI: 10.1038/s41598-018-28333-w] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
31 Febbraio M, Roy CB, Levin L. Is There a Causal Link Between Periodontitis and Cardiovascular Disease? A Concise Review of Recent Findings. Int Dent J 2021:S0020-6539(21)00138-6. [PMID: 34565546 DOI: 10.1016/j.identj.2021.07.006] [Reference Citation Analysis]
32 Kuhnle GGC. Nutrition epidemiology of flavan-3-ols: The known unknowns. Mol Aspects Med 2018;61:2-11. [PMID: 29146101 DOI: 10.1016/j.mam.2017.10.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
33 Califf RM. Warning About Shortcuts in Drug Development. J Am Heart Assoc 2017;6:e005737. [PMID: 28325714 DOI: 10.1161/JAHA.117.005737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
34 Seshia SS. A 'reluctant' critical review: 'Manual for evidence-based clinical practice (2015)'. J Eval Clin Pract 2015;21:995-1005. [PMID: 26726034 DOI: 10.1111/jep.12509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
35 Mattes WB, Goodsaid F. Regulatory landscapes for biomarkers and diagnostic tests: Qualification, approval, and role in clinical practice. Exp Biol Med (Maywood) 2018;243:256-61. [PMID: 29110507 DOI: 10.1177/1535370217739629] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
36 Stankovic G, Milasinovic D. The role of manual aspiration thrombectomy in the management of STEMI: a TOTALly different TASTE of TAPAS. Postepy Kardiol Interwencyjnej 2016;12:3-5. [PMID: 26966442 DOI: 10.5114/pwki.2016.56942] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Boney O, Moonesinghe SR, Myles PS, Grocott MPW; StEP-COMPAC group. Core Outcome Measures for Perioperative and Anaesthetic Care (COMPAC): a modified Delphi process to develop a core outcome set for trials in perioperative care and anaesthesia. Br J Anaesth 2021:S0007-0912(21)00622-X. [PMID: 34740438 DOI: 10.1016/j.bja.2021.09.027] [Reference Citation Analysis]
38 Scott BL, Lee CS, Strelzow JA. Five-Year Risk of Conversion to Total Knee Arthroplasty After Operatively Treated Periarticular Knee Fractures in Patients Over 40 Years of Age. J Arthroplasty 2020;35:2084-2089.e1. [PMID: 32317199 DOI: 10.1016/j.arth.2020.03.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]